Pouchitis
45
8
9
16
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
15.6%
7 terminated out of 45 trials
69.6%
-16.9% vs benchmark
24%
11 trials in Phase 3/4
38%
6 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (45)
GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis
Outcomes From Hyperbaric Oxygen (HBO2) Treatment for Emerging Indications
Stem Cells for the Treatment of Pouchitis
Etrasimod as Prevention of Pouchitis
The Role of Secondary Bile Acids in Intestinal Inflammation
CLF065 for Chronic Pouchitis
the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis
Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the Pouch
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
Fecal Microbiota Transplant for Patients With Chronic Pouchitis
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis
Exploring the Influence of Trptophan on the Treatment of Pouchitis
Stelara fOr ChRonic AntibioTic rEfractory pouchitiS
Fecal Microbiota Transplantation for Pouchitis
Efficacy of Liraglutide Therapy in Patients With IPAA
Inflammatory Bowel Diseases Remission Registry
Tofacitinib For Treatment Of Chronic Pouchitis
Assessment of Patients With Acute Pouchitis Treated With Antibiotics
Treating Chronic Pouchitis With a Low FODMAP Diet